Zacks.com on MSN9h
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's DrugThe EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...
Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...
Angle (LON:AGL) is a small share that's skyrocketed in recent weeks. Why does this investor hold the high-risk penny stock?
24/7 Wall St. on MSN1h
The Dow Jones Industrials Are Winning 2025: 4 Highest-Yielding Dogs of the Dow Are StealsThe Dow Jones industrial average (DJIA) is a price-weighted average of 30 blue-chip U.S. stocks, often industry leaders. It ...
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback